Medical Technology Acceleration Service Limited (‘MTAS”), an Australian based, medical technology fund.
  • A funding and advisory platform for early-stage Med-Tech assets with high growth potential.
  • Founders have decades of high returns in both the private and public markets
  • Investments in high potential med tech companies in Australia, New Zealand and the USA.
  • Pre-IPO offering and will be publicly listed in 2023; anticipated to list at a multiple of the current entry price subject to market conditions.
  • Opum Technologies - Wearable technologies for musculoskeletal treatment and proprietary health data. USD 2 billion in knee brace sales alone. Supported by the University of Auckland (NZ).
  • Clinx – Day treatment facilities servicing rapidly growing outpatient / elective surgery space.
  • Mirus - Industry leading aged care advisory and workforce optimisation SaaS with 12-year history and scaling growth. Most trusted brand in the sector and deep longstanding public & private system integrations via superior tech
  • Prostacare - Break-through treatment for benign prostate growth addressing a very large and well understood unmet need. Pre-commercialisation supported by clinically validated efficacy and robust FDA & TGA pathways
  • ‘Med-Tech Acceleration Services’ is based in Sydney
  • MTAS finances high growth emerging health sector assets
  • ROI target of 3-5 times within 24 months of taking a position
  • Unique domain expertise, a proven model & strong track record
  • De-risked assets in co-investment portfolio
  • Break-through & patented BPH treatment
  • Fills huge unmet market need between medications & much more invasive procedures
  • Proven efficacy with low pain & low cost
  • Endorsed by world-leading urologists
  • Australia’s leading aged care advisor
  • Most trusted brand in aged care
  • Strong revenues, margin & growth profile
  • Market dominant with many natural acquirers
  • Recognised as world’s leading knee sensor
  • Going-to-market with leading knee brace makers
  • Clinically proven for osteoarthritis care
  • Setting the standard for the massive growth sector of Remote Patient Monitoring